A BILL 
To amend title XVIII of the Social Security Act to provide 
for a temporary payment increase under the Medicare 
program for certain biosimilar biological products to en-
courage the development and use of such products. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Bolstering Innovative 
4
Options to Save Immediately on Medicines Act’’ or the 
5
‘‘BIOSIM Act’’. 
6
22:32 Jun 07, 2021
H2815
2 
•HR 2815 IH
SEC. 2. TEMPORARY INCREASE IN MEDICARE PART B PAY-
1
MENT FOR CERTAIN BIOSIMILAR BIOLOGI-
2
CAL PRODUCTS. 
3
Section 1847A(b)(8) of the Social Security Act (42 
4
U.S.C. 1395w–3a(b)(8)) is amended— 
5
(1) by redesignating subparagraphs (A) and 
6
(B) as clauses (i) and (ii), respectively, and moving 
7
the margin of each such redesignated clause 2 ems 
8
to the right; 
9
(2) by striking ‘‘PRODUCT.—The amount’’ and 
10
inserting the following: ‘‘PRODUCT.— 
11
‘‘(A) IN
GENERAL.—Subject to subpara-
12
graph (B), the amount’’; and 
13
(3) by adding at the end the following new sub-
14
paragraph: 
15
‘‘(B) TEMPORARY PAYMENT INCREASE.— 
16
‘‘(i) IN GENERAL.—In the case of a 
17
qualifying biosimilar biological product 
18
that is furnished during the applicable 5- 
19
year period for such product, the amount 
20
specified in this paragraph for such prod-
21
uct with respect to such period is the sum 
22
determined under subparagraph (A), ex-
23
cept that clause (ii) of such subparagraph 
24
shall be applied by substituting ‘8 percent’ 
25
for ‘6 percent’. 
26
22:32 Jun 07, 2021
H2815
3 
•HR 2815 IH
‘‘(ii) APPLICABLE 5-YEAR PERIOD.— 
1
For purposes of clause (i), the applicable 
2
5-year period for a biosimilar biological 
3
product is— 
4
‘‘(I) in the case of such a product 
5
for which payment was made under 
6
this paragraph as of December 31, 
7
2021, the 5-year period beginning on 
8
January 1, 2022; and 
9
‘‘(II) in the case of such a prod-
10
uct for which payment is first made 
11
under this paragraph during a cal-
12
endar quarter during the period be-
13
ginning January 1, 2022, and ending 
14
December 31, 2026, the 5-year period 
15
beginning on the first day of such cal-
16
endar quarter during which such pay-
17
ment is first made. 
18
‘‘(iii) QUALIFYING
BIOSIMILAR
BIO-
19
LOGICAL
PRODUCT
DEFINED.—For pur-
20
poses of this subparagraph, the term 
21
‘qualifying biosimilar biological product’ 
22
means a biosimilar biological product de-
23
scribed in paragraph (1)(C) with respect to 
24
which— 
25
22:32 Jun 07, 2021
H2815
4 
•HR 2815 IH
‘‘(I) in the case of a product de-
1
scribed in clause (ii)(I), the average 
2
sales price is not more than the aver-
3
age sales price for the reference bio-
4
logical product; and 
5
‘‘(II) in the case of a product de-
6
scribed in clause (ii)(II), the wholesale 
7
acquisition cost is not more than the 
8
wholesale acquisition cost for the ref-
9
erence biological product’’. 
10
Æ 
22:32 Jun 07, 2021
H2815
